Abstracts tagged "lupus nephritis and neutrophils"

Abstract Number: 766 • 2018 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Laura Patricia Whittall¹, Diana Gómez-Martín¹, Jiram Torres-Ruíz², Alejandro Zentella Dehesa¹, Miguel Tapia-Rodríguez¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Current evidence suggests that neutrophils play an important role in the pathophysiology of lupus nephritis (LN) mainly through the secretion of type I IFN…
Abstract Number: 1748 • 2016 ACR/ARHP Annual Meeting
Effects of Anti-High Mobility Group Box 1 Antibody for MRL/Lpr lupus-Prone Mice
Haruki Watanabe¹, Katsue S. Watanabe¹, Keyue Liu², Minglu Yan¹, Sumie Hiramatsu¹, Sonia Zeggar¹, Keiji Ohashi¹, Eri Katsuyama¹, Yoshia Miyawaki¹, Michiko Morishiata³, Takayuki Katsuyama¹, Mariko Narazaki¹, Noriko Tatebe¹, Tomoko Kawabata¹, Ken-ei Sada¹, Masahiro Nishibori² and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose: High mobility group box 1 (HMGB1) is a ubiquitous non-histone nuclear protein that exerts proinflammatory functions in the extracellular milieu. Here we evaluate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].